Comparison of ceftizoxime and cefazolin in respiratory tract infection —the second report ceftizoxime 2g vs cefazolin 4g (well controlled study)

Kenzo Shiot; Fumio Mik; Tomokazu Asa; Kenji Kub; Kenji Takamatsl; Masakazu Kohno; Keizo Beppi; Makoto Murai; Yutaka Osak; Tsugio Tera; Shosaku Abi; Hiroshi Yaguch; Takashi Mikam; Katsuo Suzuki; Yuichi Sasak; Youko Moriyam; Rensuke Kuroda; Kouichi Nasuhara; Jutarou Shimomura; Kazunori Harada; Kiyoshi Kond; Hironobl Kakizaki; Shigeo Hasegawa; Yasumichi Kat; Akira Saito; Katsuhiko Matsui; Masumi Tomisawa; Kazuo Takebe; Yoshihiro Kumasaka; Hisashi Nakamata; Shiro Kosaka; Mitsuo Nakamura; Kenichi Imamura; Seiichi Murakami; Kazuo Sasaki; Shijichiro Yoshida; Mitsuaki Yoshioica; Syoko Narita; Kenichi Kimura; Tamotsu Takishima; Sumio Arai; Kiyoshi Konno; Kotaro Oizumi; Akira Watanabe; Seiichi Aonuma; Izumi Hayashi; Tsugushi Ito; Shingo Arai; Shigeo Takizawa; Kunio Imataka; Kenichi Okayama; Masataka Katsu; Keimei Mashimo; Sumio Yamaoka; Keiichi Nakagawa; Yoshiaki Kawaguchi; Hiroaki Nakazawa; Kentaro Watanabe; Masaru Koyama; Hiroyuki Kobayashi; Junzaburo Kabe; Mikihisa Suehara; Hiroyoshi Ishibashi; Yutaka Hayakawa; Yoshio Kobayashi; Ippei Fujimori; Hajimu Takeda; Masanaga Takato; Seiko Kawashima; Fusanosuke Yamasaku; Yasutoshi Suzuki; Osamu Sekine; Yoshimaru Usuda; Nobuki Aoki; Yasuko Yuasa; Nobuo Oya; Mitsuru Hayase; Kaoru Ohyama; Kuninori Suzuki; Toshiyuki Yamamoto; Masahito Kato; Hirohiko Nagasaka; Kozo Mor; Saburo Kitaura; Kunio Nanj; Joichi Kato; Toshihiko Takeuchi; Katsutaka Torikai; Mototaka Sugiura; Teruo Katayama; Takashi Kobayashi; Mitsuru Iwakura; Keisuke Nishiwaki; Takahiro Tsujimoto; Kenichi Shimizu; Rinzo Soejima; Toshiharu Matsushima; Yoshihiko Tano; Yoshihito Niki; Yukio Nishimoto; Michio Yamakido; Masao Kuwahara; Kazuaki Takeuchi; Osamu Kurimura; Kazue Sadamoto; Hideo Sasaki; Eiro Tsubura; Yoshihiro Takishita; Tsuneo Ishibashi; Masahiro Takamoto; Masahiko Kamatani; Kohei Hara; Atsushi Saito; Masao Nakatomi; Masaru Nasu; Kinichi Izumikawa; Yoshiteru Shigenc; Rokushi Oka; Masamoto Nakano; Akira Ikebe; Hisashi Ishikawa; Kazuhiro Okuno; Keizo Yamaguchi; Tatsuo Tomita; Norimasa Ohno; Norihiko Nakahara

doi:10.11250/chemotherapy1953.29.994

Comparison of ceftizoxime and cefazolin in respiratory tract infection —the second report ceftizoxime 2g vs cefazolin 4g (well controlled study)

Kenzo Shiot, Fumio Mik, Tomokazu Asa, Kenji Kub, Kenji Takamatsl, Masakazu Kohno, Keizo Beppi, Makoto Murai, Yutaka Osak, Tsugio Tera, Shosaku Abi, Hiroshi Yaguch, Takashi Mikam, Katsuo Suzuki, Yuichi Sasak, Youko Moriyam, Rensuke Kuroda, Kouichi Nasuhara, Jutarou Shimomura, Kazunori HaradaKiyoshi Kond, Hironobl Kakizaki, Shigeo Hasegawa, Yasumichi Kat, Akira Saito, Katsuhiko Matsui, Masumi Tomisawa, Kazuo Takebe, Yoshihiro Kumasaka, Hisashi Nakamata, Shiro Kosaka, Mitsuo Nakamura, Kenichi Imamura, Seiichi Murakami, Kazuo Sasaki, Shijichiro Yoshida, Mitsuaki Yoshioica, Syoko Narita, Kenichi Kimura, Tamotsu Takishima, Sumio Arai, Kiyoshi Konno, Kotaro Oizumi, Akira Watanabe, Seiichi Aonuma, Izumi Hayashi, Tsugushi Ito, Shingo Arai, Shigeo Takizawa, Kunio Imataka, Kenichi Okayama, Masataka Katsu, Keimei Mashimo, Sumio Yamaoka, Keiichi Nakagawa, Yoshiaki Kawaguchi, Hiroaki Nakazawa, Kentaro Watanabe, Masaru Koyama, Hiroyuki Kobayashi, Junzaburo Kabe, Mikihisa Suehara, Hiroyoshi Ishibashi, Yutaka Hayakawa, Yoshio Kobayashi, Ippei Fujimori, Hajimu Takeda, Masanaga Takato, Seiko Kawashima, Fusanosuke Yamasaku, Yasutoshi Suzuki, Osamu Sekine, Yoshimaru Usuda, Nobuki Aoki, Yasuko Yuasa, Nobuo Oya, Mitsuru Hayase, Kaoru Ohyama, Kuninori Suzuki, Toshiyuki Yamamoto, Masahito Kato, Hirohiko Nagasaka, Kozo Mor, Saburo Kitaura, Kunio Nanj, Joichi Kato, Toshihiko Takeuchi, Katsutaka Torikai, Mototaka Sugiura, Teruo Katayama, Takashi Kobayashi, Mitsuru Iwakura, Keisuke Nishiwaki, Takahiro Tsujimoto, Kenichi Shimizu, Rinzo Soejima, Toshiharu Matsushima, Yoshihiko Tano, Yoshihito Niki, Yukio Nishimoto, Michio Yamakido, Masao Kuwahara, Kazuaki Takeuchi, Osamu Kurimura, Kazue Sadamoto, Hideo Sasaki, Eiro Tsubura, Yoshihiro Takishita, Tsuneo Ishibashi, Masahiro Takamoto, Masahiko Kamatani, Kohei Hara, Atsushi Saito, Masao Nakatomi, Masaru Nasu, Kinichi Izumikawa, Yoshiteru Shigenc, Rokushi Oka, Masamoto Nakano, Akira Ikebe, Hisashi Ishikawa, Kazuhiro Okuno, Keizo Yamaguchi, Tatsuo Tomita, Norimasa Ohno, Norihiko Nakahara

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The therapeutic efficacy, adverse reactions and usefulness of ceftizoxime (FK 749, CZX) were objectively compared with those of cefazolin (CEZ) in 230 patients with chronic respiratory tract infection or pneumonia in the well controlled study at 33 institutions in Japan. Patients were given daily ceftizoxime 2 g or cefazolin 4 g by i. v. drip infusion for, in principle, 14 days. The results were as follows: 1) No significant difference in therapeutic efficacy was observed between the patients with respiratory tract infection given ceftizoxime 2 g/day and cefazolin 4 g/day. 2) The therapeutic efficacy of ceftizoxime 2 g/day was significantly superior to that of cefazolin 4 g/day except in patients with elevated mycoplasmal antibody and/or cold hemagglutinin titer. 3) The improvement in sputum volume of patients with pneumonia or lung abscess was significantly better in the cefazolin group than in the ceftizoxime group on the 3 rd day of dosing and in patients with respiratory tract infection except pneumonia and lung abscess, on the 14 th day of dosing. 4) The eradication rate of causative organisms isolated from patients was significantly higher in the ceftizoxime group than in the cefazolin group. 5) No significant difference was noted between the two drug groups in incidence of adverse reactions. These findings suggest that the therapeutic efficacy of ceftizoxime 2 g/day on bacterial respiratory tract infection is more excellent than that of cefazolin 4 g/day.

Original language	English
Pages (from-to)	994-1043
Number of pages	50
Journal	Chemotherapy
Volume	29
Issue number	9
DOIs	https://doi.org/10.11250/chemotherapy1953.29.994
Publication status	Published - 1981
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.29.994

Cite this

Shiot, K., Mik, F., Asa, T., Kub, K., Takamatsl, K., Kohno, M., Beppi, K., Murai, M., Osak, Y., Tera, T., Abi, S., Yaguch, H., Mikam, T., Suzuki, K., Sasak, Y., Moriyam, Y., Kuroda, R., Nasuhara, K., Shimomura, J., ... Nakahara, N. (1981). Comparison of ceftizoxime and cefazolin in respiratory tract infection —the second report ceftizoxime 2g vs cefazolin 4g (well controlled study). Chemotherapy, 29(9), 994-1043. https://doi.org/10.11250/chemotherapy1953.29.994

Shiot, K, Mik, F, Asa, T, Kub, K, Takamatsl, K, Kohno, M, Beppi, K, Murai, M, Osak, Y, Tera, T, Abi, S, Yaguch, H, Mikam, T, Suzuki, K, Sasak, Y, Moriyam, Y, Kuroda, R, Nasuhara, K, Shimomura, J, Harada, K, Kond, K, Kakizaki, H, Hasegawa, S, Kat, Y, Saito, A, Matsui, K, Tomisawa, M, Takebe, K, Kumasaka, Y, Nakamata, H, Kosaka, S, Nakamura, M, Imamura, K, Murakami, S, Sasaki, K, Yoshida, S, Yoshioica, M, Narita, S, Kimura, K, Takishima, T, Arai, S, Konno, K, Oizumi, K, Watanabe, A, Aonuma, S, Hayashi, I, Ito, T, Arai, S, Takizawa, S, Imataka, K, Okayama, K, Katsu, M, Mashimo, K, Yamaoka, S, Nakagawa, K, Kawaguchi, Y, Nakazawa, H, Watanabe, K, Koyama, M, Kobayashi, H, Kabe, J, Suehara, M, Ishibashi, H, Hayakawa, Y, Kobayashi, Y, Fujimori, I, Takeda, H, Takato, M, Kawashima, S, Yamasaku, F, Suzuki, Y, Sekine, O, Usuda, Y, Aoki, N, Yuasa, Y, Oya, N, Hayase, M, Ohyama, K, Suzuki, K, Yamamoto, T, Kato, M, Nagasaka, H, Mor, K, Kitaura, S, Nanj, K, Kato, J, Takeuchi, T, Torikai, K, Sugiura, M, Katayama, T, Kobayashi, T, Iwakura, M, Nishiwaki, K, Tsujimoto, T, Shimizu, K, Soejima, R, Matsushima, T, Tano, Y, Niki, Y, Nishimoto, Y, Yamakido, M, Kuwahara, M, Takeuchi, K, Kurimura, O, Sadamoto, K, Sasaki, H, Tsubura, E, Takishita, Y, Ishibashi, T, Takamoto, M, Kamatani, M, Hara, K, Saito, A, Nakatomi, M, Nasu, M, Izumikawa, K, Shigenc, Y, Oka, R, Nakano, M, Ikebe, A, Ishikawa, H, Okuno, K, Yamaguchi, K, Tomita, T, Ohno, N & Nakahara, N 1981, 'Comparison of ceftizoxime and cefazolin in respiratory tract infection —the second report ceftizoxime 2g vs cefazolin 4g (well controlled study)', Chemotherapy, vol. 29, no. 9, pp. 994-1043. https://doi.org/10.11250/chemotherapy1953.29.994

@article{9a6e39174e314ee08bfe69eaf661432f,

title = "Comparison of ceftizoxime and cefazolin in respiratory tract infection —the second report ceftizoxime 2g vs cefazolin 4g (well controlled study)",

abstract = "The therapeutic efficacy, adverse reactions and usefulness of ceftizoxime (FK 749, CZX) were objectively compared with those of cefazolin (CEZ) in 230 patients with chronic respiratory tract infection or pneumonia in the well controlled study at 33 institutions in Japan. Patients were given daily ceftizoxime 2 g or cefazolin 4 g by i. v. drip infusion for, in principle, 14 days. The results were as follows: 1) No significant difference in therapeutic efficacy was observed between the patients with respiratory tract infection given ceftizoxime 2 g/day and cefazolin 4 g/day. 2) The therapeutic efficacy of ceftizoxime 2 g/day was significantly superior to that of cefazolin 4 g/day except in patients with elevated mycoplasmal antibody and/or cold hemagglutinin titer. 3) The improvement in sputum volume of patients with pneumonia or lung abscess was significantly better in the cefazolin group than in the ceftizoxime group on the 3 rd day of dosing and in patients with respiratory tract infection except pneumonia and lung abscess, on the 14 th day of dosing. 4) The eradication rate of causative organisms isolated from patients was significantly higher in the ceftizoxime group than in the cefazolin group. 5) No significant difference was noted between the two drug groups in incidence of adverse reactions. These findings suggest that the therapeutic efficacy of ceftizoxime 2 g/day on bacterial respiratory tract infection is more excellent than that of cefazolin 4 g/day.",

author = "Kenzo Shiot and Fumio Mik and Tomokazu Asa and Kenji Kub and Kenji Takamatsl and Masakazu Kohno and Keizo Beppi and Makoto Murai and Yutaka Osak and Tsugio Tera and Shosaku Abi and Hiroshi Yaguch and Takashi Mikam and Katsuo Suzuki and Yuichi Sasak and Youko Moriyam and Rensuke Kuroda and Kouichi Nasuhara and Jutarou Shimomura and Kazunori Harada and Kiyoshi Kond and Hironobl Kakizaki and Shigeo Hasegawa and Yasumichi Kat and Akira Saito and Katsuhiko Matsui and Masumi Tomisawa and Kazuo Takebe and Yoshihiro Kumasaka and Hisashi Nakamata and Shiro Kosaka and Mitsuo Nakamura and Kenichi Imamura and Seiichi Murakami and Kazuo Sasaki and Shijichiro Yoshida and Mitsuaki Yoshioica and Syoko Narita and Kenichi Kimura and Tamotsu Takishima and Sumio Arai and Kiyoshi Konno and Kotaro Oizumi and Akira Watanabe and Seiichi Aonuma and Izumi Hayashi and Tsugushi Ito and Shingo Arai and Shigeo Takizawa and Kunio Imataka and Kenichi Okayama and Masataka Katsu and Keimei Mashimo and Sumio Yamaoka and Keiichi Nakagawa and Yoshiaki Kawaguchi and Hiroaki Nakazawa and Kentaro Watanabe and Masaru Koyama and Hiroyuki Kobayashi and Junzaburo Kabe and Mikihisa Suehara and Hiroyoshi Ishibashi and Yutaka Hayakawa and Yoshio Kobayashi and Ippei Fujimori and Hajimu Takeda and Masanaga Takato and Seiko Kawashima and Fusanosuke Yamasaku and Yasutoshi Suzuki and Osamu Sekine and Yoshimaru Usuda and Nobuki Aoki and Yasuko Yuasa and Nobuo Oya and Mitsuru Hayase and Kaoru Ohyama and Kuninori Suzuki and Toshiyuki Yamamoto and Masahito Kato and Hirohiko Nagasaka and Kozo Mor and Saburo Kitaura and Kunio Nanj and Joichi Kato and Toshihiko Takeuchi and Katsutaka Torikai and Mototaka Sugiura and Teruo Katayama and Takashi Kobayashi and Mitsuru Iwakura and Keisuke Nishiwaki and Takahiro Tsujimoto and Kenichi Shimizu and Rinzo Soejima and Toshiharu Matsushima and Yoshihiko Tano and Yoshihito Niki and Yukio Nishimoto and Michio Yamakido and Masao Kuwahara and Kazuaki Takeuchi and Osamu Kurimura and Kazue Sadamoto and Hideo Sasaki and Eiro Tsubura and Yoshihiro Takishita and Tsuneo Ishibashi and Masahiro Takamoto and Masahiko Kamatani and Kohei Hara and Atsushi Saito and Masao Nakatomi and Masaru Nasu and Kinichi Izumikawa and Yoshiteru Shigenc and Rokushi Oka and Masamoto Nakano and Akira Ikebe and Hisashi Ishikawa and Kazuhiro Okuno and Keizo Yamaguchi and Tatsuo Tomita and Norimasa Ohno and Norihiko Nakahara",

year = "1981",

doi = "10.11250/chemotherapy1953.29.994",

language = "English",

volume = "29",

pages = "994--1043",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "9",

}

TY - JOUR

T1 - Comparison of ceftizoxime and cefazolin in respiratory tract infection —the second report ceftizoxime 2g vs cefazolin 4g (well controlled study)

AU - Shiot, Kenzo

AU - Mik, Fumio

AU - Asa, Tomokazu

AU - Kub, Kenji

AU - Takamatsl, Kenji

AU - Kohno, Masakazu

AU - Beppi, Keizo

AU - Murai, Makoto

AU - Osak, Yutaka

AU - Tera, Tsugio

AU - Abi, Shosaku

AU - Yaguch, Hiroshi

AU - Mikam, Takashi

AU - Suzuki, Katsuo

AU - Sasak, Yuichi

AU - Moriyam, Youko

AU - Kuroda, Rensuke

AU - Nasuhara, Kouichi

AU - Shimomura, Jutarou

AU - Harada, Kazunori

AU - Kond, Kiyoshi

AU - Kakizaki, Hironobl

AU - Hasegawa, Shigeo

AU - Kat, Yasumichi

AU - Saito, Akira

AU - Matsui, Katsuhiko

AU - Tomisawa, Masumi

AU - Takebe, Kazuo

AU - Kumasaka, Yoshihiro

AU - Nakamata, Hisashi

AU - Kosaka, Shiro

AU - Nakamura, Mitsuo

AU - Imamura, Kenichi

AU - Murakami, Seiichi

AU - Sasaki, Kazuo

AU - Yoshida, Shijichiro

AU - Yoshioica, Mitsuaki

AU - Narita, Syoko

AU - Kimura, Kenichi

AU - Takishima, Tamotsu

AU - Arai, Sumio

AU - Konno, Kiyoshi

AU - Oizumi, Kotaro

AU - Watanabe, Akira

AU - Aonuma, Seiichi

AU - Hayashi, Izumi

AU - Ito, Tsugushi

AU - Arai, Shingo

AU - Takizawa, Shigeo

AU - Imataka, Kunio

AU - Okayama, Kenichi

AU - Katsu, Masataka

AU - Mashimo, Keimei

AU - Yamaoka, Sumio

AU - Nakagawa, Keiichi

AU - Kawaguchi, Yoshiaki

AU - Nakazawa, Hiroaki

AU - Watanabe, Kentaro

AU - Koyama, Masaru

AU - Kobayashi, Hiroyuki

AU - Kabe, Junzaburo

AU - Suehara, Mikihisa

AU - Ishibashi, Hiroyoshi

AU - Hayakawa, Yutaka

AU - Kobayashi, Yoshio

AU - Fujimori, Ippei

AU - Takeda, Hajimu

AU - Takato, Masanaga

AU - Kawashima, Seiko

AU - Yamasaku, Fusanosuke

AU - Suzuki, Yasutoshi

AU - Sekine, Osamu

AU - Usuda, Yoshimaru

AU - Aoki, Nobuki

AU - Yuasa, Yasuko

AU - Oya, Nobuo

AU - Hayase, Mitsuru

AU - Ohyama, Kaoru

AU - Suzuki, Kuninori

AU - Yamamoto, Toshiyuki

AU - Kato, Masahito

AU - Nagasaka, Hirohiko

AU - Mor, Kozo

AU - Kitaura, Saburo

AU - Nanj, Kunio

AU - Kato, Joichi

AU - Takeuchi, Toshihiko

AU - Torikai, Katsutaka

AU - Sugiura, Mototaka

AU - Katayama, Teruo

AU - Kobayashi, Takashi

AU - Iwakura, Mitsuru

AU - Nishiwaki, Keisuke

AU - Tsujimoto, Takahiro

AU - Shimizu, Kenichi

AU - Soejima, Rinzo

AU - Matsushima, Toshiharu

AU - Tano, Yoshihiko

AU - Niki, Yoshihito

AU - Nishimoto, Yukio

AU - Yamakido, Michio

AU - Kuwahara, Masao

AU - Takeuchi, Kazuaki

AU - Kurimura, Osamu

AU - Sadamoto, Kazue

AU - Sasaki, Hideo

AU - Tsubura, Eiro

AU - Takishita, Yoshihiro

AU - Ishibashi, Tsuneo

AU - Takamoto, Masahiro

AU - Kamatani, Masahiko

AU - Hara, Kohei

AU - Saito, Atsushi

AU - Nakatomi, Masao

AU - Nasu, Masaru

AU - Izumikawa, Kinichi

AU - Shigenc, Yoshiteru

AU - Oka, Rokushi

AU - Nakano, Masamoto

AU - Ikebe, Akira

AU - Ishikawa, Hisashi

AU - Okuno, Kazuhiro

AU - Yamaguchi, Keizo

AU - Tomita, Tatsuo

AU - Ohno, Norimasa

AU - Nakahara, Norihiko

PY - 1981

Y1 - 1981

N2 - The therapeutic efficacy, adverse reactions and usefulness of ceftizoxime (FK 749, CZX) were objectively compared with those of cefazolin (CEZ) in 230 patients with chronic respiratory tract infection or pneumonia in the well controlled study at 33 institutions in Japan. Patients were given daily ceftizoxime 2 g or cefazolin 4 g by i. v. drip infusion for, in principle, 14 days. The results were as follows: 1) No significant difference in therapeutic efficacy was observed between the patients with respiratory tract infection given ceftizoxime 2 g/day and cefazolin 4 g/day. 2) The therapeutic efficacy of ceftizoxime 2 g/day was significantly superior to that of cefazolin 4 g/day except in patients with elevated mycoplasmal antibody and/or cold hemagglutinin titer. 3) The improvement in sputum volume of patients with pneumonia or lung abscess was significantly better in the cefazolin group than in the ceftizoxime group on the 3 rd day of dosing and in patients with respiratory tract infection except pneumonia and lung abscess, on the 14 th day of dosing. 4) The eradication rate of causative organisms isolated from patients was significantly higher in the ceftizoxime group than in the cefazolin group. 5) No significant difference was noted between the two drug groups in incidence of adverse reactions. These findings suggest that the therapeutic efficacy of ceftizoxime 2 g/day on bacterial respiratory tract infection is more excellent than that of cefazolin 4 g/day.

AB - The therapeutic efficacy, adverse reactions and usefulness of ceftizoxime (FK 749, CZX) were objectively compared with those of cefazolin (CEZ) in 230 patients with chronic respiratory tract infection or pneumonia in the well controlled study at 33 institutions in Japan. Patients were given daily ceftizoxime 2 g or cefazolin 4 g by i. v. drip infusion for, in principle, 14 days. The results were as follows: 1) No significant difference in therapeutic efficacy was observed between the patients with respiratory tract infection given ceftizoxime 2 g/day and cefazolin 4 g/day. 2) The therapeutic efficacy of ceftizoxime 2 g/day was significantly superior to that of cefazolin 4 g/day except in patients with elevated mycoplasmal antibody and/or cold hemagglutinin titer. 3) The improvement in sputum volume of patients with pneumonia or lung abscess was significantly better in the cefazolin group than in the ceftizoxime group on the 3 rd day of dosing and in patients with respiratory tract infection except pneumonia and lung abscess, on the 14 th day of dosing. 4) The eradication rate of causative organisms isolated from patients was significantly higher in the ceftizoxime group than in the cefazolin group. 5) No significant difference was noted between the two drug groups in incidence of adverse reactions. These findings suggest that the therapeutic efficacy of ceftizoxime 2 g/day on bacterial respiratory tract infection is more excellent than that of cefazolin 4 g/day.

UR - http://www.scopus.com/inward/record.url?scp=0019800893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019800893&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.29.994

DO - 10.11250/chemotherapy1953.29.994

M3 - Article

AN - SCOPUS:0019800893

SN - 0009-3165

VL - 29

SP - 994

EP - 1043

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

IS - 9

ER -

Comparison of ceftizoxime and cefazolin in respiratory tract infection —the second report ceftizoxime 2g vs cefazolin 4g (well controlled study)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this